<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2020-08-08</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2259</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?</article-title><trans-title-group xml:lang="ru"><trans-title>Сердечно-сосудистая коморбидность: пациент с ишемической болезнью сердца и атеросклерозом периферических артерий. Как выявить и управлять рисками ишемических событий?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барбараш Ольга Леонидовна – доктор медицинских наук, профессор, член-корреспондент РАН, директор</p><p>650002, Кемерово, Сосновый бульвар, 6 </p></bio><bio xml:lang="en"><p>Olga L. Barbarash – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director</p><p>Sosnoviy bulv. 6, Kemerovo, 650002 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашталап</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kashtalap</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кашталап Василий Васильевич – доктор медицинских наук, доцент, заведующая отделом клинической кардиологии</p><p>650002, Кемерово, Сосновый бульвар, 6 </p></bio><bio xml:lang="en"><p>Vasiliy V. Kashtalap – MD, PhD, Head of Clinical Cardiology Department</p><p>Sosnoviy bulv. 6, Kemerovo, 650002 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шибанова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shibanova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шибанова Ирина Александровна – кандидат медицинских наук, старший научный сотрудник, лаборатория реабилитации, отдел клинической кардиологии</p><p>650002, Кемерово, Сосновый бульвар, 6 </p></bio><bio xml:lang="en"><p>Irina A. Shibanova – MD, PhD, Senior Researcher, Laboratory of Rehabilitation, Clinical Cardiology Department</p><p>Sosnoviy bulv. 6, Kemerovo, 650002 </p></bio><email xlink:type="simple">shibia@kemcardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2020</year></pub-date><volume>16</volume><issue>4</issue><fpage>607</fpage><lpage>613</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Barbarash O.L., Kashtalap V.V., Shibanova I.A., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Барбараш О.Л., Кашталап В.В., Шибанова И.А.</copyright-holder><copyright-holder xml:lang="en">Barbarash O.L., Kashtalap V.V., Shibanova I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2259">https://www.rpcardio.online/jour/article/view/2259</self-uri><abstract><p>Modern data on comorbidity in coronary artery disease (CAD) are presented in the article, as well as its frequency, dependence on the age, clinical and prognostic significance, and increasing relevance for practical health care. The positions of one of the components of cardiovascular comorbidity – multifocal atherosclerosis – are presented. The existing approaches to the detection and clinical assessment of multifocal atherosclerosis, as well as to the management of the high risk of ischemic events in such patients, are outlined. The main positions on the prevention of the risk of cardiovascular complications in patients with CAD and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies. Promising possibilities of using such a therapeutic approach to the management of comorbid patients in routine clinical practice are presented.</p></abstract><trans-abstract xml:lang="ru"><p>В обзорной статье представлены современные данные о феномене коморбидности при ишемической болезни сердца (ИБС), обозначены ее частота, зависимость от возраста, клинико-прогностическая значимость и возрастающая актуальность для практического здравоохранения. Представлены позиции одной из составляющих сердечно-сосудистой коморбидности – мультифокального атеросклероза. Обозначены существующие подходы к выявлению и клинической оценке мультифокального атеросклероза, а также к управлению высоким риском ишемических событий у таких пациентов. На основании результатов проведенных клинических исследований выделены основные позиции по профилактике риска сердечно-сосудистых осложнений у пациентов с сочетанием ИБС и атеросклероза периферических артерий с помощью комбинации антикоагулянта – ривароксабана и антиагреганта – ацетилсалициловой кислоты. Представлены перспективные возможности использования такого терапевтического подхода к ведению коморбидных пациентов в рутинной клинической практике.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мультифокальный атеросклероз</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>коморбидность</kwd><kwd>прогноз</kwd><kwd>ривароксабан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multifocal atherosclerosis</kwd><kwd>coronary artery disease</kwd><kwd>comorbidity</kwd><kwd>prognosis</kwd><kwd>rivaroxaban</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Концевая А. В., Муканеева Д. К., Мырзаматова А. О., др. Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году. Кардиоваскулярная Терапия и Профилактика. 2020;19(1):23-96. DOI:10.15829/1728-8800-2020-1-2396.</mixed-citation><mixed-citation xml:lang="en">Kontsevaya A.V., Mukaneeva D.K., Myrzamatova A.O., et al. Economic damage of risk factors due to their contribution to morbidity and mortality from major chronic noncommunicable diseases in the Russian Federation in 2016. Cardiovascular Therapy and Prevention. 2020; 19 (1): 23-96 (In Russ.) DOI:10.15829/1728-8800-2020-1-2396.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Шальнова С.А., Никонов Е.Л., и др., от имени участников исследования ЭГИДА-Москва. Эпидемиологический мониторинг факторов риска и здоровья в мегаполисе (ЭГИДА-МОСКВА). Социально-демографические характеристики населения. Профилактическая Медицина. 2020;23(1):69-76. DOI:10.17116/profmed20202301169.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Shalnova S.A., Nikonov E.L., et al., on behalf of the participants in the EGIDA-Moscow study. Epidemiological monitoring of risk factors and health in the metropolis (EGIDA-MOSCOW). Socio-demographic characteristics of the population. Preventive Medicine. 2020;23(1):69-76 (In Russ.) DOI:10.17116/profmed20202301169.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Menotti A., Puddu P.E., Kromhout D., et al. Coronary heart disease mortality trends during 50 years as explained by risk factor changes: The European cohorts of the Seven Countries Study. Eur J Prev Cardiol. 2020;27:988-98. DOI:10.1177/2047487318821250.</mixed-citation><mixed-citation xml:lang="en">Menotti A., Puddu P.E., Kromhout D., et al. Coronary heart disease mortality trends during 50 years as explained by risk factor changes: The European cohorts of the Seven Countries Study. Eur J Prev Cardiol. 2020;27:988-98. DOI:10.1177/2047487318821250.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Komajda M., Cosentino F., Ferrari R., et al. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. Eur J Prev Cardiol. 2020;2047487320912491. DOI:10.1177/2047487320912491.</mixed-citation><mixed-citation xml:lang="en">Komajda M., Cosentino F., Ferrari R., et al. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. Eur J Prev Cardiol. 2020;2047487320912491. DOI:10.1177/2047487320912491.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Knuuti J., Wijns W., Saraste A., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77. DOI:10.1093/eurheartj/ehz425.</mixed-citation><mixed-citation xml:lang="en">Knuuti J., Wijns W., Saraste A., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77. DOI:10.1093/eurheartj/ehz425.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная Терапия и Профилактика. 2019;18:5-66. DOI:10.15829/1728-8800-2019-1-5-66.</mixed-citation><mixed-citation xml:lang="en">Oganov R.G., Simanenkov V.I., Bakulin I.G., et al. Comorbid pathology in clinical practice. Algorithms for diagnosis and treatment. Cardiovascular Therapy and Prevention. 2019;18:5-66 (In Russ.) DOI:10.15829/1728-8800-2019-1-5-66.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Salive M.E. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75-83. DOI:10.1093/epirev/mxs009.</mixed-citation><mixed-citation xml:lang="en">Salive M.E. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75-83. DOI:10.1093/epirev/mxs009.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Самородская И.В., Ларина В.Н., Лукьянов М.М. Вопросы организации помощи пациентам с мультиморбидной патологией: аналитический обзор международных и российских рекомендаций. Профилактическая Медицина. 2019;22:107¬14. DOI:10.17116/profmed201922021107.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Samorodskaya I.V., Larina V.N., Lukyanov M.M. Questions of organization of care for patients with multimorbid pathology: an analytical review of international and Russian recommendations. Preventive Medicine. 2019;22:107-14 (In Russ.) DOI:10.17116/profmed201922021107.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Шутов А.М., Ефремов Е.В. Коморбидность, мультиморбидность, двойной диагноз – синонимы или разные понятия? Кардиоваскулярная Терапия и Профилактика. 2019;18:65-9. DOI:10.15829/1728-8800-2019-2-65-69.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Shutov A.M., Efremov E.V. Comorbidity, multimorbidity, dual diagnosis - synonyms or different concepts? Cardiovascular Therapy and Prevention. 2019;18:65-9 (In Russ.) DOI:10.15829/1728-8800-2019-2-65-69.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Зыков М.В., Кашталап В.В., Быкова И.С., и др. Связь мультиморбидности с риском развития сердечно¬сосудистых осложнений у пациентов с острым коронарным синдромом. Кардиологический Вестник. 2018;2:59-65. DOI:10.17116/Cardiobulletin201813259.</mixed-citation><mixed-citation xml:lang="en">Zykov M.V., Kashtalap V.V., Bykova I.S., et al. Relationship of multimorbidity with the risk of cardiovascular complications in patients with acute coronary syndrome. Cardiological Bulletin. 2018;2:59- 65 (In Russ.) DOI:10.17116/Cardiobulletin201813259.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Marengoni A., Angleman S., Melis R., et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430-9. DOI:10.1016/j.arr.2011.03.003.</mixed-citation><mixed-citation xml:lang="en">Marengoni A., Angleman S., Melis R., et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430-9. DOI:10.1016/j.arr.2011.03.003.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Valderas J.M., Starfield B., Sibbald B., et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357-63. DOI:10.1370/afm.983.</mixed-citation><mixed-citation xml:lang="en">Valderas J.M., Starfield B., Sibbald B., et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357-63. DOI:10.1370/afm.983.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-68. DOI:10.1016/0021-9681(70)90054-8.</mixed-citation><mixed-citation xml:lang="en">Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-68. DOI:10.1016/0021-9681(70)90054-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wong C., Gange S.J., Moore R.D., et al. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2018;66:1230-8. DOI:10.1093/cid/cix998.</mixed-citation><mixed-citation xml:lang="en">Wong C., Gange S.J., Moore R.D., et al. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2018;66:1230-8. DOI:10.1093/cid/cix998.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Семенов В.Ю., Самородская И.В., и др. Коморбидная патология у больных ишемической болезнью сердца при коронарном шунтировании: опыт двух кардиохирургических центров. Российский Кардиологический Журнал. 2017;3:6-13. DOI:10.15829/1560-4071-2017-3-6-13</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Semenov V.Yu., Samorodskaya I.V., et al. Comorbid pathology in patients with coronary artery disease with coronary artery bypass grafting: experience of two cardiac surgery centers. Russian Cardiological Journal. 2017;3:6-13 (In Russ.) DOI:10.15829/1560-4071-2017-3-6-13</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Белялов Ф.И. Выбор и классификация лекарственных препаратов при коморбидных заболеваниях. Архивъ Внутренней Медицины. 2020;10:57-60. DOI:10.20514/2226-6704-2020-10-1-57-60.</mixed-citation><mixed-citation xml:lang="en">Belyalov F.I. Selection and classification of drugs for comorbid diseases. Archive of Internal Medicine. 2020;10:57-60 (In Russ.) DOI:10.20514/2226-6704-2020-10-1-57-60.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Белялов Ф.И. Проблемы коморбидности при заболеваниях внутренних органов. Вестник Современной Клинической Медицины. 2010;3:44-7.</mixed-citation><mixed-citation xml:lang="en">Belyalov F.I. Comorbidity problems in diseases of internal organs. Bulletin of Modern Clinical Medicine. 2010;3:44-7 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Белялов Ф.И. Подходы к персонализированной терапии. Рациональная Фармакотерапия в Кардиологии. 2018;14(3):418-24. DOI: 10.20996/1819-6446-2018-14-3-418-424.</mixed-citation><mixed-citation xml:lang="en">Belyalov F.I. Personalized therapy approaches. Rational Pharmacotherapy in Cardiology. 2018;14(3):418-24 (In Russ.) DOI: 10.20996/1819-6446-2018-14-3-418-424.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262-7. DOI:10.1136/bmj.38695.605440.AE.</mixed-citation><mixed-citation xml:lang="en">Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262-7. DOI:10.1136/bmj.38695.605440.AE.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt D.L., Steg P..G, Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-9. DOI:10.1001/jama.295.2.180.</mixed-citation><mixed-citation xml:lang="en">Bhatt D.L., Steg P..G, Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-9. DOI:10.1001/jama.295.2.180.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sorbets E., Greenlaw N., Ferrari R., et al. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol. 2017;40:797-806. DOI:10.1002/clc.22730.</mixed-citation><mixed-citation xml:lang="en">Sorbets E., Greenlaw N., Ferrari R., et al. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol. 2017;40:797-806. DOI:10.1002/clc.22730.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sorbets E., Fox K.M., Elbez Y., et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020;41:347-56. DOI:10.1093/eurheartj/ehz660.</mixed-citation><mixed-citation xml:lang="en">Sorbets E., Fox K.M., Elbez Y., et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020;41:347-56. DOI:10.1093/eurheartj/ehz660.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Crowe F., Zemedikun D.T., Okoth K., et al. Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK. Heart. 2020;106:810-6. DOI:10.1136/heartjnl-2019-316091.</mixed-citation><mixed-citation xml:lang="en">Crowe F., Zemedikun D.T., Okoth K., et al. Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK. Heart. 2020;106:810-6. DOI:10.1136/heartjnl-2019-316091.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Панченко Е.П. Результаты трехлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH). Кардиология. 2009;49:9-15.</mixed-citation><mixed-citation xml:lang="en">Panchenko E.P. Results of a three-year follow-up of outpatients with clinical manifestations of atherothrombosis (analysis of the Russian population of the REACH register). Kardiologiia. 2009;49:9-15 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Воевода М.И., Галстян Г.Р., и др. Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений. Российский Кардиологический Журнал. 2019;4:83-91. DOI:10.15829/1560-4071-2019-4-83-91.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Voevoda M.I., Galstyan G.R., et al. Prediabetes as an interdisciplinary problem: definition, risks, approaches to the diagnosis and prevention of type 2 diabetes mellitus and cardiovascular complications. Russian Cardiological Journal. 2019;4:83-91 (In Russ.) DOI:10.15829/1560-4071-2019-4-83-91.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486.</mixed-citation><mixed-citation xml:lang="en">Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Бокерия Л.А., Покровский А.В. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 2019. Ангиология и Сосудистая Хирургия. 2019;25(2) приложение 2:1-109.</mixed-citation><mixed-citation xml:lang="en">Bockeria L.A., Pokrovsky A.V. National guidelines for the diagnosis and treatment of diseases of the arteries of the lower extremities 2019. Angiology and Vascular Surgery. 2019;25(2) Appendix 2:1- 109 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Зыков М.В., Кашталап В.В. и др. Острый коронарный синдром, почечная дисфункция и мультифокальный атеросклероз: общие патогенетические механизмы и современные аспекты проблемы. Кемерово: Кузбассвузиздат; 2016.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Zykov M.V., Kashtalap V.V., et al. Acute coronary syndrome, renal dysfunction and multifocal atherosclerosis: general pathogenetic mechanisms and modern aspects of the problem. Kemerovo: Kuzbassvuzizdat; 2016 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-821. DOI:10.1093/eurheartj/ehx095.</mixed-citation><mixed-citation xml:lang="en">Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-821. DOI:10.1093/eurheartj/ehx095.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gallino A., Aboyans V., Diehm C., et al. Non-coronary atherosclerosis. Eur Heart J. 2014;35:1112- 9. DOI:10.1093/eurheartj/ehu071.</mixed-citation><mixed-citation xml:lang="en">Gallino A., Aboyans V., Diehm C., et al. Non-coronary atherosclerosis. Eur Heart J. 2014;35:1112- 9. DOI:10.1093/eurheartj/ehu071.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Кашталап В.В. Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом. Как оптимизировать прогноз? Медицинский Совет. 2018;16:32-8 DOI:10.21518/2079-701X2018-16-32-38.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Kashtalap V.V. A patient with ischemic heart disease and multifocal atherosclerosis. How to optimize your forecast? Medical Advice. 2018;16:32-8 (In Russ.) DOI:10.21518/2079-701X2018-16-32-38.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Сумин А.Н., Гайфулин Р.А., Безденежных А.В., и др. Распространенность мультифокального атеросклероза в различных возрастных группах. Кардиология. 2012;52:28-34.</mixed-citation><mixed-citation xml:lang="en">Sumin A.N., Gaifulin R.A., Bezdenezhnykh A.V., et al. The prevalence of multifocal atherosclerosis in different age groups. Kardiologiia. 2012;52:28-34 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные Проблемы Сердечно-сосудистых Заболеваний. 2012;1:12-6. DOI:10.17802/2306-1278-2012-1-12-16.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Kashtalap V.V. Detection of latent non-coronary atherosclerosis in patients with acute coronary syndrome. Is there any reason? Complex Problems of Cardiovascular Diseases. 2012; 1:12-6 (In Russ.) DOI:10.17802/2306-1278-2012-1-12-16.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Subherwal S., Bhatt D.L., Li S., et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:541-549. DOI:10.1161/CIRCOUTCOMES.111.964379.</mixed-citation><mixed-citation xml:lang="en">Subherwal S., Bhatt D.L., Li S., et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:541-549. DOI:10.1161/CIRCOUTCOMES.111.964379.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira-González I., Permanyer Miralda G., Heras M., et al. Prognosis and management of patients with acute coronary syndrome and polyvascular disease. Rev Esp Cardiol. 2009;62:1012-21. DOI:10.1016/s1885-5857(09)73267-0.</mixed-citation><mixed-citation xml:lang="en">Ferreira-González I., Permanyer Miralda G., Heras M., et al. Prognosis and management of patients with acute coronary syndrome and polyvascular disease. Rev Esp Cardiol. 2009;62:1012-21. DOI:10.1016/s1885-5857(09)73267-0.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee D., Eagle K.A., Kline-Rogers E., et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100(1):1-6. DOI:10.1016/j.amjcard.2007.02.046.</mixed-citation><mixed-citation xml:lang="en">Mukherjee D., Eagle K.A., Kline-Rogers E., et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100(1):1-6. DOI:10.1016/j.amjcard.2007.02.046.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Al Thani H., El-Menyar A., Alhabib K.F., et al. Polyvascular disease in patients presenting with acute coronary syndrome: its predictors and outcomes. Sci World J. 2012;2012:284851. DOI:10.1100/2012/284851.</mixed-citation><mixed-citation xml:lang="en">Al Thani H., El-Menyar A., Alhabib K.F., et al. Polyvascular disease in patients presenting with acute coronary syndrome: its predictors and outcomes. Sci World J. 2012;2012:284851. DOI:10.1100/2012/284851.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Barbarash O.L., Zykov M.V., Pecherina T.B., et al. The Prognostic Value of Peripheral Artery Diseases in Patients with ST-Segment Elevation Myocardial Infarction. Dis Marker. 2013;35:877-82. DOI:10.1155/2013/487807.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Zykov M.V., Pecherina T.B., et al. The Prognostic Value of Peripheral Artery Diseases in Patients with ST-Segment Elevation Myocardial Infarction. Dis Marker. 2013;35:877-82. DOI:10.1155/2013/487807.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-206. DOI:10.1001/jama.297.11.1197.</mixed-citation><mixed-citation xml:lang="en">Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-206. DOI:10.1001/jama.297.11.1197.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Комаров, А. Л., Панченко Е. П. Частота поражений различных сосудистых бассейнов и медикаментозное лечение больных с высоким риском атеротромботических осложнений. Российские результаты международного исследования AGATHA. Кардиология. 2004;11:97-102.</mixed-citation><mixed-citation xml:lang="en">Komarov A.L., Panchenko E.P. Frequency of lesions of various vascular basins and drug treatment of patients with a high risk of atherothrombotic complications. Russian results of the AGATHA international study. Kardiologiia. 2004;11:97-102 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Тарловская Е.И. Коморбидность и полиморбидность – современная трактовка и насущные задачи, стоящие перед терапевтическим сообществом. Кардиология. 2018;58(S9):29-38. DOI:10.18087/cardio.2562.</mixed-citation><mixed-citation xml:lang="en">Tarlovskaya E.I. Comorbidity and polymorbidity is a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018;58(S9):29-38 (In Russ.) DOI:10.18087/cardio.2562.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. DOI:10.1056/NEJMoa060989.</mixed-citation><mixed-citation xml:lang="en">Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. DOI:10.1056/NEJMoa060989.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Morrow D.A., Braunwald E., Bonaca M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-13. DOI:10.1056/NEJMoa1200933.</mixed-citation><mixed-citation xml:lang="en">Morrow D.A., Braunwald E., Bonaca M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-13. DOI:10.1056/NEJMoa1200933.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.</mixed-citation><mixed-citation xml:lang="en">Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Steg P.G., Bhatt D.L., Simon T., et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-20. DOI:10.1056/NEJMoa1908077.</mixed-citation><mixed-citation xml:lang="en">Steg P.G., Bhatt D.L., Simon T., et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-20. DOI:10.1056/NEJMoa1908077.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom J.W., Connolly S.J., Bosch J., et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. DOI:10.1056/NEJMoa1709118.</mixed-citation><mixed-citation xml:lang="en">Eikelboom J.W., Connolly S.J., Bosch J., et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. DOI:10.1056/NEJMoa1709118.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">de Vries T.I., Eikelboom J.W., Bosch J., et al. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur Heart J. 2019;40(46):3771-8a. DOI:10.1093/eurheartj/ehz404.</mixed-citation><mixed-citation xml:lang="en">de Vries T.I., Eikelboom J.W., Bosch J., et al. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur Heart J. 2019;40(46):3771-8a. DOI:10.1093/eurheartj/ehz404.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly S.J., Eikelboom J.W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.</mixed-citation><mixed-citation xml:lang="en">Connolly S.J., Eikelboom J.W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Anand S.S., Eikelboom J.W., Dyal L., et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019;73(25):3271-80. DOI:10.1016/j.jacc.2019.02.079.</mixed-citation><mixed-citation xml:lang="en">Anand S.S., Eikelboom J.W., Dyal L., et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019;73(25):3271-80. DOI:10.1016/j.jacc.2019.02.079.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
